Who Supplies Pazopanib to India from SLOVENIA

To import finished pharmaceutical formulations containing Pazopanib into India, the importing company must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40 or 41, along with the necessary documentation, to the CDSCO for approval. The registration process includes providing a No Objection Certificate (NOC) from the manufacturer, ensuring compliance with the Drugs and Cosmetics Act, and obtaining approval from the Drug Controller General of India (DCGI). The timeline for import drug registration can vary, but it typically takes several months to complete. For Pazopanib formulations under HS Code 30049049, specific requirements may include stability data, clinical trial data, and evidence of Good Manufacturing Practice (GMP) compliance.

Imported pharmaceutical formulations containing Pazopanib must undergo quality testing at CDSCO-approved laboratories in India. This includes batch-wise testing to ensure each batch meets the required standards. A Certificate of Analysis (CoA) from the manufacturer, along with stability data (preferably in ICH Zone IV conditions), must be provided. The formulations must comply with the Indian Pharmacopoeia standards. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the products.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations, including Pazopanib. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Slovenia may have facilitated smoother trade relations, but specific details are not available.

India imports finished Pazopanib formulations due to the presence of patented or branded products not manufactured domestically, specific dosage forms required for patient treatment, and limitations in domestic manufacturing capacity. The market size for Pazopanib formulations in India is significant, with a total export market of $8.3 million across 109 exporters to 57 countries.

The Basic Customs Duty (BCD) for HS Code 30049049 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, amounting to 1%. The Integrated Goods and Services Tax (IGST) is levied at 12%. There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) applicable to this product. Exemptions or concessional rates may apply under specific trade agreements or government notifications.

India sources finished Pazopanib formulations from Slovenia due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China, Germany, and the United States. Slovenia's share in the Indian market for Pazopanib formulations is not specified.

India imports finished Pazopanib formulations from Slovenia due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. These formulations may not be manufactured domestically, necessitating imports to meet patient treatment requirements.

Compared to other origins such as China, Germany, and the United States, Slovenia offers competitive advantages in terms of quality, regulatory compliance, and reliability. Specific details regarding price comparisons and Slovenia's unique advantages are not available.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Specific instances of past shortages are not available.

1. 1Consider dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement comprehensive inventory planning to ensure consistent supply.
3. 3Establish clear payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain Importer Exporter Code (IEC) from DGFT.
2. 2Register the product with CDSCO by submitting Form 40 or 41.
3. 3Provide a No Objection Certificate (NOC) from the manufacturer.
4. 4Ensure compliance with the Drugs and Cosmetics Act.
5. 5Obtain approval from the Drug Controller General of India (DCGI).
6. 6Provide stability data and clinical trial data as required.
7. 7Ensure Good Manufacturing Practice (GMP) compliance.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF).
5. 5Stability data (preferably in ICH Zone IV conditions).
6. 6Free Sale Certificate.
7. 7Manufacturer authorization letter.

Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the imported formulations. Mandatory batch testing is performed, including sample collection and analysis. Timelines for testing can vary, and if a batch fails, it may be rejected or require reprocessing. Common quality issues from Slovenian imports are not specified.

1. 1Renew CDSCO registration annually.
2. 2Conduct periodic audits of the Slovenian manufacturing facility.
3. 3Implement change control procedures.
4. 4Establish pharmacovigilance systems.
5. 5Monitor post-import quality and safety.
6. 6Maintain import records as per the Drugs and Cosmetics Act.